Caren van Roekel

204 Chapter 7 22. van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, et al. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases. J Nucl Med. 2016;57(7):1014-9. Epub 2016/02/26. 23. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53(22):6591-603. Epub 2008/11/04. 24. Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, et al. (90)Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI research. 2018;8(1):60. Epub 2018/07/15. 25. Jongen JMJ, Rosenbaum C, Braat M, van den Bosch M, Sze DY, Kranenburg O, et al. Anatomic versus metabolic tumor response assessment after radioembolization treatment. J Vasc Interv Radiol. 2018;29(2):244-53 e2. Epub 2017/12/19. 26. Sager S, Akgun E, Uslu-Besli L, Asa S, Akovali B, Sahin O, et al. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after y ttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma. Nucl Med Comm. 2019;40(5):461-8. Epub 2019/03/22. 27. Bastiaannet R, Lodge MA , de Jong H, Lam M. The unique role of fluorodeox yglucose - PE T in radioembolization. PET Clinics. 2019;14(4):447-57. Epub 2019/09/02. 28. Willowson KP, Hayes AR, Chan DLH, Tapner M, Bernard EJ, Maher R, et al. Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. EJNMMI Research. 2017;7(1):46. Epub 2017/05/26. 29. Dendy MS, Ludwig JM, KimHS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget. 2017;8(23):37912-22. 30. Garin E. A multicentric and randomized study demonstrating the impact of MAA based dosimetry on tumor response in SIRT for HCC. 2019 [cited 2019 December 12]; Available from: https://www. eventscribe.com/2019/GEST/fsPopup. asp?Mode=presInfo&PresentationID= 521844.